{"id":"W2889599863","doi":"10.1200/jco.2017.35.15_suppl.tps3113","title":"INDUCE-1: A phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Tolerability; Immunogenicity; Agonist; Immunotherapy; Pharmacokinetics; Antibody; CD28; Pharmacodynamics; Internal medicine; Oncology; Biomarker; Cytokine release syndrome; Cancer; Pharmacology; T cell; Immunology; Immune system; Chimeric antigen receptor; Adverse effect; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001229758,0.002332325,0.002052859,0.0007278971,0.0005053966,0.001205458,0.001111731,0.001468895,0.003609578],"category_scores_gemma":[0.0006947685,0.0008438061,0.001442735,0.0005213599,0.001340325,0.001553254,0.0004125507,0.003652516,0.001217319],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001401693,"about_ca_system_score_gemma":0.001912988,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001175266,"about_ca_topic_score_gemma":0.003124618,"domain_scores_codex":[0.9996073,0.0001507402,0.00001618284,0.00008492508,0.00004366181,0.00009724905],"domain_scores_gemma":[0.9992818,0.00009367832,0.0001797075,0.00006479619,0.00004080717,0.0003390868],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5702199,0.2336209,0.00642273,0.00119623,0.001238851,0.0004086311,0.000574534,0.004308366,0.07876433,0.0005860344,0.005286028,0.09737346],"study_design_scores_gemma":[0.3513947,0.6325577,0.006821173,0.00002920856,0.0003474663,0.0002914055,0.00008092371,0.001077154,0.005078995,0.0001948467,0.002094477,0.00003198982],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9905325,0.001738164,0.0006741307,0.0003662341,0.0001232431,0.003351895,0.001368818,0.0001468826,0.001698061],"genre_scores_gemma":[0.9876598,0.001833175,0.001516992,0.000719275,0.0001974363,0.003142705,0.002210865,0.00004713867,0.002672647],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003609578,"threshold_uncertainty_score":0.01207519,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1265322001903863,"score_gpt":0.5105342624420508,"score_spread":0.3840020622516646,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}